We are pleased to present below all posts archived in 'June, 2017'. If you still can't find what you are looking for, try using the search box.
DiaSorin and Tecan Group have announced that they have agreed to collaborate in a development under which DiaSorin will make use of Tecan’s Fluent® Laboratory Automation Solution as its nucleic acid extraction platform. The new platform will be used in combination with the DiaSorin Liaison® MDX PCR system to provide the customer with a complete sample to result system for molecular diagnostics.
Read the rest of entry »
Investment will help commercialize Cytox’s services for testing for Alzheimer’s disease and grow Cytox as a leader in this area
15 June 2017, Oxford & Alderley Park, UK. Cytox, an emerging precision medicine leader providing genetic testing for Alzheimer’s disease, has announced that it has raised £2.6m (approx $3.3m) to fund the commercial launch and international roll out of its comprehensive testing service. The funding round was led by the GM&C Life Sciences Fund, managed by Catapult Ventures, alongside existing and new investors, including Perivoli Innovations, The Rainbow Seed Fund, The University of Oxford and private investors.
Cardiff, UK – 21st June 2017 – EKF Diagnostics, the global in vitro diagnostics company, announces that a recent study has confirmed that its Quo-Test® A1c point-of-care testing (POCT) analyzer shows comparable performance to a lab-based HPLC system for the measurement of glycated hemoglobin (HbA1c). Recently published in Practical Laboratory Medicine , the study undertaken by the Diabetes Research Unit Cymru, Swansea University, UK, also observed that under the correct circumstances using WHO guidelines Quo-Test is appropriate for the diagnosis of Type 2 diabetes.
The TOPRA Annual Symposium is the largest forum for European regulatory professionals to meet up, discuss current regulatory issues and debate future plans for regulation.
SYDNEY, AUSTRALIA -- 05/06/17 -- SpeeDx Pty, Ltd. today announced an agreement with Cepheid for distribution of its PlexPCRTM and ResistancePlusTM molecular diagnostic products in key markets throughout Europe. The agreement, covering Germany, France, Italy, and the UK, will increase coverage for the market-leading ResistancePlus MG test, the first CE-IVD test for Mycoplasma genitalium to combine detection with testing for azithromycin resistance.
Partnership aimed at the development of molecular diagnostic assays on Biocartis’ fully automated Idylla™ platform
London (UK) / Mechelen (Belgium), 7 June 2017 – MRC Technology (‘MRCT’), a medical research charity, and Biocartis Group NV (‘Biocartis’ or the ‘Company’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announced a partnership to develop selected molecular diagnostic tests for use on Biocartis’ fully automated Idylla™ platform. MRCT aims to move promising medical research forward into patient treatments and diagnostics and has been involved in helping deliver a number of therapies including Keytruda® (pembrolizumab, marketed by MSD) which is an important immunotherapy treatment for various cancers.
BBI Solutions, in partnership with Merck and Kinematic Automation, is hosting a lateral flow seminar designed to provide a practical insight into lateral flow test development. Taking place from the 6th to the 8th of June at the Fota Island Resort in Cork, Ireland, this event is aimed at industry professionals, and will cover various aspects of assay development and commercialisation, as well as offering a hands-on experience in test design.
BBI Solutions (BBI) has invested into its facilities and resource in order to increase the capacity of cell culture transferrin production by up to 40%.
Who are the BIVDA Members
Member Press Releases
Point of Care Directory
News, Policy and Media
BIVDA Press Releases